A method of isolating and purifying a product of sugar alcohol or anhydrosugar alcohol hydrogenolysis from a reaction mixture containing sorbitans, 1,2,4-butanetriol (BTO), 1,2,5,6-hexanetetrol (HTO), among other byproducts of a hydrogenolysis reaction of a sugar alcohol and/or a mono- or di-dehydrative product of a sugar alcohol is described. The method involves contacting the mixture having the products of sugar alcohol or anhydrosugar alcohol hydrogenation and other C.sub.1-C.sub.6 alcohols and polyols with a resin material adapted for chromatography under conditions where the products preferentially associates with the resin relative to other components in the mixture, and eluting products from the resin with a solvent. The method suggests a way for separation of aliphatic polyols generated from the hydrogenolysis of sugar alcohols or anhydrosugar alcohols.

A process for producing a pentaerythritol mercaptocarboxylic acid ester of the present invention includes: a step of reacting pentaerythritol with a mercaptocarboxylic acid, in which an absorbance of a 5 wt % aqueous solution of the pentaerythritol at a wavelength of 270 nm, which is measured using a quartz cell having an optical path length of 50 mm, is 0.07 or less.

A process for preparing materials derived from sugar alcohols such that the dehydration products exhibit better accountability and improved color to water-clear or near water-white appearance is described. In particular, the process involves employing a reducing Brnsted acid (e.g., phosphonic acid) for the catalysis of sugar alcohols to their corresponding dehydrated-cyclized products.

A process for preparing materials derived from sugar alcohols such that the dehydration products exhibit better accountability and improved color to water-clear or near water-white appearance is described. In particular, the process involves employing a reducing Brnsted acid (e.g., phosphonic acid) for the catalysis of sugar alcohols to their corresponding dehydrated-cyclized products.

The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, pancreatitius, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, pancreatitius, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

A process of forming a polyurethane material includes forming an unsaturated alcohol from an unsaturated plant oil via a reduction reaction. The process includes forming an alkyne-terminated alcohol from the unsaturated alcohol and forming a polyol having two primary hydroxyl groups from the alkyne-terminated alcohol. The process further includes polymerizing a mixture that includes the polyol having the two primary hydroxyl groups to form a polyurethane material.

A process of forming a polyurethane material includes forming an unsaturated alcohol from an unsaturated plant oil via a reduction reaction. The process includes forming an alkyne-terminated alcohol from the unsaturated alcohol and forming a polyol having two primary hydroxyl groups from the alkyne-terminated alcohol. The process further includes polymerizing a mixture that includes the polyol having the two primary hydroxyl groups to form a polyurethane material.

A process of forming a polyurethane material includes forming an unsaturated alcohol from an unsaturated plant oil via a reduction reaction. The process includes forming an alkyne-terminated alcohol from the unsaturated alcohol and forming a polyol having two primary hydroxyl groups from the alkyne-terminated alcohol. The process further includes polymerizing a mixture that includes the polyol having the two primary hydroxyl groups to form a polyurethane material.

A process of forming a polyurethane material includes forming an unsaturated alcohol from an unsaturated plant oil via a reduction reaction. The process includes forming an alkyne-terminated alcohol from the unsaturated alcohol and forming a polyol having two primary hydroxyl groups from the alkyne-terminated alcohol. The process further includes polymerizing a mixture that includes the polyol having the two primary hydroxyl groups to form a polyurethane material.